GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer:Database mining for GATA family members in malignancies by Lin, Hao-Yu et al.
  
 University of Groningen
GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lin, H-Y., Zeng, D., Liang, Y-K., Wei, X-L., & Chen, C-F. (2017). GATA3 and TRPS1 are distinct
biomarkers and prognostic factors in breast cancer: Database mining for GATA family members in
malignancies. Oncotarget, 8(21), 34750-34761. https://doi.org/10.18632/oncotarget.16160
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget34750www.impactjournals.com/oncotarget
GATA3 and TRPS1 are distinct biomarkers and prognostic factors 
in breast cancer: database mining for GATA family members in 
malignancies








Correspondence to: Hao-yu Lin, email: Rainlhy@stu.edu.cn
Keywords: GATA, breast cancer, database mining, prognostic values, chemosensitivity
Received: January 10, 2017    Accepted: February 13, 2017    Published: March 13, 2017
Copyright: Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
GATA transcription factors are zinc finger DNA binding proteins that activate 
transcription during development and cell differentiation. To date, 7 members of GATA 
family have been reported. However, the expression patterns and the exact roles of 
distinct GATA family members contributing to tumorigenesis and progression of breast 
cancer (BC) remain to be elucidated. Here, we studied the expression of GATA transcripts 
in a variety of tumor types compared with the normal controls using the ONCOMINE 
and GOBO databases, along with their corresponding expression profiles in an array 
of cancer cell lines through CCLE analysis. Based on Kaplan-Meier plotter, we further 
investigated the prognostic values of GATA members specifically high expressed in BC 
patients. It was found that, when compared with normal tissues, GATA3 and TRPS1 were 
distinctly high expressed in BC patients among all GATA members. GATA3 expression was 
significantly associated with ESR1, while TRPS1 was correlated with ERBB2. In survival 
analysis, GATA3 and TRPS1 mRNA high expressions were correlated to better survival in 
BC patients, and TRPS1 high expression was significantly associated with longer RFS in 
patients who have received chemotherapy. These results suggest that GATA3 and TRPS1 
are distinct biomarkers and essential prognostic factors for breast cancer.
INTRODUCTION
Breast cancer (BC) remains the top cancer and 
the principle cause of death from cancer in women 
worldwide [1]. Disorder in development of mammary 
epithelia is a prominent process contributing to 
tumorigenesis of BC [2].
Abnormality in a variety of genes, as well as 
signaling pathways, is reported to be responsible for 
aberrant growth and differentiation of mammary epithelia, 
such as GATA, Notch and Wnt, etc [3–5]. GATA has been 
identified as one of the transcription factors that play an 
essential role during epithelial proliferation [6–8], which 
comprised family members sharing highly conserved zinc 
fingers that recognize the motif WGATAR to mediate 
DNA binding and protein interactions [9].
GATA1, GATA2 and GATA3 were termed 
hematopoietic GATA factors [10, 11], while GATA4, 
GATA5, and GATA6 were categorized as endodermal 
GATA factors [12]. GATA1 and GATA2 play pivotal roles 
in regulating cell cycle or proliferation [13]. GATA3 is 
estimated to be the most abundant transcription factor 
in luminal epithelial cells expression and is required for 
normal development of the mammary gland [14, 15]. 
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GATA4, GATA5 and GATA6 are expressed in distinct but 
overlapping patterns [16–18]. GATA4 and GATA5 tend 
to mark fully differentiated epithelial cells, while GATA6 
expresses in the immature proliferating cells [19]. TRPS-
1 (trichorhinophalangeal syndrome-1) is a novel GATA 
transcription factor that has been found to be a critical 
activator of mesenchymal-to-epithelial transition (MET) 
during embryonic development in a number of tissues, 
including bone, cartilage and kidney [20].
Recently, Marjokein and Zheng et al. have reviewed 
the emerging role of GATA transcription factors in 
malignancies [6, 9], suggesting the distinctive role of 
individual GATA member in cancer development and 
progression. Although GATA has been identified as a 
crucial transcription factors in a variety of hematogenous 
malignancies and solid tumors [9, 21], the functions of 
different GATA members in contribution to tumorigenesis 
in BC are largely unknown.
In the current study, we extended the research field 
to breast cancers based on large databases, with purpose 
of determining the expression pattern of distinct GATA 
family members in breast cancer VS. normal tissues and the 
correlations with characteristic molecular markers, as well 
as their corresponding prognostic values in breast cancer.
RESULTS
GATA3 and TRPS1 are distinctively 
overexpressed in breast cancer among all GATA 
family members
Hitherto, 7 GATA family members have been 
identified in human cancers, including hematological 
malignancies and solid tumors (Figure 1). ONCOMINE 
analysis revealed that GATA3 mRNA expression was 
significantly higher in BC than normal samples across a 
wide variety of datasets in different cancer types. GATA3 
transcripts were 6.103 fold elevated in breast cancer 
samples as compared with normal tissues in a dataset 
with 593 samples that derived from TCGA (the Cancer 
Genome Atlas) database (Figure 2C). In another dataset 
from Zhao’s study [22], GATA3 was 3.806 fold elevated 
in breast cancer samples as compared with normal tissues 
(p=0.004) (Figure 2D).
Moreover, the analysis also demonstrated that the 
transcription level of TRPS1 was significantly elevated in 
breast cancer versus. normal samples. TRPS1 was 2.634 
fold increased (p=8.33e-7) in the largest dataset with 593 
samples from TCGA. Consistently, in another dataset from 
Sorlie’s study [23], TRPS1 was 2.338 fold increased in 
cancer VS. normal samples (p=0.001).
However, no significant difference was found in the 
mRNA level of other GATA members, including GATA1 
(1.24 fold change, p=0.172), GATA2 (1.452 fold change, 
p=0.014), GATA4 (2.12 fold change, p=0.843), GATA5 
(1.212 fold change, p=1.99e-4) and GATA6 (1.537 fold 
change, p=0.903), between breast cancer samples and 
normal controls (Figure 2A, 2B, 2E, 2F and 2G).
In addition, CCLE analysis was consistent with that 
of ONCOMINE demonstrating that GATA3 and TRPS1 
were distinctively up-regulated in breast cancer cell 
lines, while other GATA members were present at a low 
transcription level or absent in breast cancer cells (Figure 
3A and 3B). These results implied that GATA3 and TRPS1 
were different from other GATA members that distinctively 
high expressed in breast cancer, suggesting they might 
play unique roles in the development of breast cancer. The 
mRNA expressions of other GATA members evaluated 
in different breast cancer cell lines were provided in 
Supplementary Figures (Supplementary Figures 1-5).
The co-expression analysis of GATA3 and 
TRPS1 in different molecular subtypes of breast 
cancer
Since GATA3 and TRPS1 were found to specifically 
high express in breast cancer among all GATA members, 
we next performed further exploration on the potential roles 
of GATA3 and TRPS1 in BC, in connection with other 
featured biomarkers according to molecular subtypes of 
breast cancer. In ONCOMINE co-expression analysis, it was 
found that GATA3 expression was significantly correlated 
with ESR1 (r=0.945) (Figure 4A), while TRPS1 expression 
was significantly correlated with ERBB2 (r=0.992) (Figure 
5A). Dataset from Farmer’s study [24] showed that GATA3 
was 10.132 fold elevated in Luminal-like BC samples as 
compared with Basal-like BC (p=6.68*10e-16) (Figure 4B).
Similar results were found in CCLE analysis, 
GATA3 over-expressed in the breast cancer cell lines 
with high level of ER expression, while under-expressed 
in those with low level or negative ESR1 expression 
(p<0.001) (Figure 4C). TRPS1 over-expressed in the 
breast cancer cell lines with high level of ERBB2 
expression, while under-expressed in those with low level 
or negative ERBB2 expression (p=0.003) (Figure 5B). The 
mRNA expressions of GATA3, TRPS1, ESR1 and ERBB2 
in BC cell lines were shown in Supplementary Table.
In GOBO analysis, the expression of GATA3 in 
luminal-like was significantly higher than basal-A or 
basal-B subtypes of breast cancer, and the hormone 
receptor (HR) sensitive subtype also expressed higher 
level of GATA3 than TN (triple-negative) and Her-2 
clinical subtypes (Figure 4D and 4E). The expression 
of TRPS1 in luminal subtypes was significantly higher 
than in basal A or basal B subtypes of BC both in tissue 
samples and cell lines (Figure 5C and 5D).
GATA3 predicts longer RFS in patients with 
ER+/Luminal subtype breast cancer
We next assessed the prognostic effect of GATA3 
in breast cancer. It was found that GATA3 mRNA high 
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expression was correlated to longer RFS in all BC patients 
(HR=0.71, p=8.4e-10) (Figure 6A). In particular, sub-
analysis revealed that GATA3 mRNA high expression 
was significantly associated with better RFS in both ER 
positive and luminal A subtype breast cancer (HR=0.82, 
p=0.0026 and (HR=0.77, p=0.0024, respectively), 
however, no significant difference was found in ER 
negative subtype, which suggested a pivotal prognostic 
value of GATA3 in ER positive or luminal subtype breast 
cancer, underlying the aberrant regulation of GATA3 in 
contributing to the tumorigenesis and development of 
hormone sensitive breast cancer (Figure 6B–6G).
TRPS1 high mRNA expression is correlated 
to better RFS in patients with breast cancer, 
particularly in the subset who have received 
chemotherapy
In Figure 7, TRPS1 high mRNA expression was 
significantly associated with longer RFS in all BC patients 
Figure 1: The mRNA expression pattern of GATA family members in different tumor types. This graphic showed the 
numbers of datasets with statistically significant mRNA over-expression (red) or down-expression (blue) of the target gene (cancer vs. 
normal tissue). The p value threshold is 0.01. The number in each cell represents the number of analyses that meet the threshold within 
those analysis and cancer types. The gene rank was analyzed by percentile of target gene in the top of all genes measured in each research. 
Cell color is determined by the best gene rank percentile for the analyses within the cell.
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(HR=0.6, p=3.6e-09) (Figure 7A). In particular, sub-
analysis revealed that high mRNA expression of TRPS1 
was significantly associated with better survival in ER 
positive (HR=0.64, p=7e-06), but not in ER negative BC 
(HR=0.76, p=0.41) (Figure 7B and 7C), furthermore, the 
results also demonstrated that TRPS1 high expression 
was significantly associated with longer RFS in luminal 
A (HR=0.67, p=0.0016), luminal B (HR=0.71, p=0.031), 
and Her-2 positive (HR=0.54, p=0.027), but not in Her-
2 subtype (HR=1.13, p=0.61), Her-2 negative (HR=0.76, 
p=0.66) or basal-like subtypes BC (HR=0.81, p=0.2) 
(Figure 7D-7I).
Of noteworthy, the results demonstrated that TRPS1 
high mRNA expression was significantly correlated to 
longer RFS in patients who have received chemotherapy 
(HR=0.6, p=0.032), indicating a potential role of TRPS1 
in contribution to chemosensitivity in breast cancer 
(Figure 7J and 7K).
DISCUSSION
Breast cancer (BC), mainly developing from the 
mammary epithelium, presents the highest prevalence and 
mortality among all malignancies in women, primarily 
attributing to resistance to chemoradiotherapy or targeted 
therapy, as well as distant metastasis [25–27]. It is 
challenging, but is going to be rewarding to illustrate the 
pathogenesis of BC, as well as to develop novel prognostic 
strategies and discover effective therapeutic approaches.
GATA family has been widely recognized as pivotal 
transcription factors in a wide range of human cancers 
[9, 28]. Our analysis suggested that, among all GATA 
members, GATA3 and TRPS1 were distinctively high-
expressed in BC compared to normal controls, implying 
their unique roles in BC.
GATA3 is essential for multi-organ development 
and regulates tissue specific differentiation, especially 
Figure 2: GATA family analysis in Breast cancer (ONCOMINE database). Box plots derived from gene expression data 
in ONCOMINE comparing expression of a specific GATA family member in normal and BC tissue. The p value was set up at 0.01 and 
fold change was defined as 2. (A) Comparison of GATA1 mRNA expression. (B) Comparison of GATA2 mRNA expression. (C-D) 
Comparison of GATA3 mRNA expression. (E) Comparison of GATA4 mRNA expression. (F) Comparison of GATA5 mRNA expression. 
(G) Comparison of GATA6 mRNA expression. (H) Comparison of TRPS1 mRNA expression.
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for the development of mammary epithelium [29]. 
Asselin-Labat, M. L. et al. reported that, in a subtype 
of human breast carcinoma, GATA3 mutation abrogated 
the DNA-binding ability, with mechanistic investigation 
revealed that GATA3 negatively regulated the tumor-
initiating capacity of mammary luminal progenitor cells 
and targets the putative tumor suppressor caspase-14 
[15].
ONCOMINE co-expression analysis demonstrated 
that GATA3 was positively correlated with the expression 
of ESR1. The result was consistent with a meta-analysis of 
human cancer microarrays by Wilson, B. J. et al revealing 
that GATA3 was integral to the estrogen receptor alpha 
pathway [30].
Study by Wenzhe Si. et al reported that dysfunction 
of the reciprocal feedback loop between GATA3 and 
Figure 3: GATA3 and TRPS1 were distinctively high expressed in breast cancer cell lines from CCLE analysis. (A) The 
mRNA expression level of GATA3 ranked the third highest in a variety of cancer cell line, behind that of retinoblastoma and T-cell-ALL, 
(shown in red frame). (B) The mRNA expression level of TRPS1 ranked the highest in breast cancer among different cancer cell types, 
(shown in red frame).
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Figure 4: The correlation analysis of GATA3 in different molecular subtypes of breast cancer. (A) In ONCOMINE analysis, 
the expression of GATA3 was significantly associated with ESR1 expression. (shown in red frame) (B) The expression of GATA3 in 
luminal-like was significantly higher than in basal-like subtypes of breast cancer. (C) In CCLE analysis, GATA3 over-expressed in the 
breast cancer cell lines with high level of ER expression, while under-expressed in those with low level or negative ER expression. (D) In 
GOBO analysis, the expression of GATA3 in luminal-like was significantly higher than in basal A or Basal B subtypes of breast cancer, and 
the Hormone Receptor (HR) subtype also express higher GATA3 than TN(Triple Negative) and HER2 clinical subtypes. (E) the expression 
of GATA3 in each cell lines.
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ZEB2-nucleated repression programs contributes 
to breast cancer metastasis, which indicated that 
expression of GATA3 in BC may associate with better 
RFS or DMFS (distant metastasis-free survival) [31]. 
Yoon et al also reported that higher levels of GATA3 
predicted better survival in women with breast cancer 
[32]. Survival analysis of GATA3 in the present study 
demonstrated similar results that over-expression of 
GATA3 was associated with better survival in patients 
with breast cancer, particularly in patients with ER 
positive or luminal subtype breast cancer, suggesting the 
tumor-suppressive role of GATA3 in hormone sensitive 
breast cancer.
TRPS1 was reported to act as a crucial transcription 
factor for the development and differentiation of normal 
tissues, such as bone, hair follicles and kidney [33, 34]. 
Nonetheless, its role in cancer progression remains 
largely unknown. Study by Wu et al proposed that TRPS1 
acted as a central hub in the control of cell cycle and 
proliferation during cancer development [35]. Our study 
found that TRPS1 was significantly high expressed both 
in BC samples and BC cell lines, and co-expressed with 
the expression of ERBB2, supporting the critical role of 
TRPS1 in BC initiation or progression.
Survival analysis indicated TRPS1 high expression 
was significantly associated with better RFS in all BC 
Figure 5: The correlation analysis of GATA3 in different molecular subtypes of breast cancer. (A) In ONCOMINE analysis, 
TRPS1 expression was significantly correlated with ERBB2 expression. (shown in red frame) (B) In CCLE analysis, TRPS1 over-expressed 
in the breast cancer cell lines with high level of ERBB2 expression, while under-expressed in those with low level or negative ERBB2 
expression. (C) In GOBO analysis, the expression of TRPS1 in different subtypes of breast cancer (E) the expression of TRPS1 in each 
cell lines.
Oncotarget34757www.impactjournals.com/oncotarget
patients, hormone sensitive and Her-2 positive BC, but 
not in ER negative, Her-2 negative or basal-like subtypes, 
which implied that TRPS1 might act as a tumor suppressor 
in BC. A recent study by Huang et al. supported the notion 
and demonstrated that down-regulation of TRPS1 promoted 
EMT in a variety of cancer cells and was correlated with 
distant metastasis, tumor recurrence and poor survival 
rate in breast cancer patients [36]. Study by Stinson also 
suggested the suppressive role of TRPS1 in BC through 
inhibiting EMT in a directly repression of ZEB2 [37].
In our study, we first reported that high TRPS1 
transcription predicted better survival in a subset of patients 
who have received chemotherapy, which was supported by 
a recent study showing that TRPS1 was associated with the 
multidrug resistance of osteosarcoma by regulating MDR1 
gene expression [38]. Furthermore, it has been recognized 
that epithelial-to-mesenchymal transition (EMT) is an 
important mechanism in contribution to chemoresistance 
in breast cancer. Therefore, it is extrapolated that TRPS1 
might be a favorable predictor of chemosensitivity in BC, 
with underlying mechanism possibly relates to suppression 
of EMT in breast cancer.
In conclusion, GATA3 and TRPS1 are distinctly 
high-expressed in breast cancer versus normal controls 
Figure 6: The prognostic values of GATA3 in breast cancer. (A) High mRNA level of GATA3 was associated with longer RFS in 
all BC patients. (B) High mRNA level of GATA3 was associated with longer RFS both in ER+, but not ER- BC patients. (C) High mRNA 
level of GATA3 was associated with longer RFS in luminal A subtype BC patients, but not in luminal B subtype BC patients. (D) High 
mRNA level of GATA3 was not associated with RFS in either HER-2 positive or basal-like subtype BC patients.
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Figure 7: The prognostic values of mRNA level of TRPS1 in breast cancer patients. (A) High mRNA level of TRPS1 was 
associated with longer RFS in all BC patients. (B) High mRNA level of TRPS1 was associated with longer RFS both in ER positive, 
but not in ER negative BC patients. (C) High mRNA level of TRPS1 was associated with longer RFS in luminal subtypes BC patients. 
(D) High mRNA level of TRPS1 is not associated with longer RFS in either luminal B or basal-like subtype BC patients. (E) High mRNA 
level of TRPS1 is associated with longer RFS in BC patients, who have received chemotherapy, while not associated with RFS in those 
haven’t received chemotherapy.
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and predict better survival in patients with BC. GATA3 
is positively associated with ESR1, while TRPS1 is 
correlated with ERBB2 and might act as a potential 
modulator of chemosensitivity in breast tumor. GATA3 
and TRPS1 are distinctive biomarkers and essential 
prognostic factors in BC.
MATERIALS AND METHODS
ONCOMINE analysis
The mRNA levels of distinct GATA family members 
in different type of cancers were determined through 
analysis in ONCOMINE database (www.oncomine.org), 
which is a publicly accessible online cancer microarray 
database to facilitate discovery from genome-wide 
expression analyses.
In this study, students’t-test was used to generate 
a p-value for comparison between cancer specimens and 
normal control datasets. The fold change was defined as 
2 and p value was set up at 0.01. Significant correlations 
can be found in an array of BC researches, as showed in 
typical figures.
CCLE analysis
The mRNA levels of GATA3 and TRPS1 in a series 
of cancers were analyzed by CCLE database (https://
portals.broadinstitute.org/ccle/home), which is an online 
encyclopedia of a compilation of gene expression, 
chromosomal copy number and massively parallel 
sequencing data from 947 human cancer cell lines, 
to facilitate the identification of genetic, lineage, and 
predictors of drug sensitivity.
GOBO analysis
The transcription levels of GATA3 and TRPS1, 
as well as their co-expression genes were analyzed by 
uploading corresponding affymetrix probes to GOBO 
database (http://co.bmc.lu.se/gobo/gsa.pl). GOBO is a 
user-friendly online tool that allows rapid assessment 
of gene expression levels, identification of co-expressed 
genes and association with outcome for single genes, gene 
sets or gene signatures in a breast cancer data set.
The tumor data set consists of samples with the 
following characteristics: all tumors (n=1881), ER+ 
tumors (n=1225), ER- tumors (n=95), untreated tumors 
(n=927), tamoxifen treated tumors (n=326).
The Kaplan-Meier plotter survival analysis
Prognostic values of featured GATA members 
that found specifically high expressed in BC samples 
were further assessed by displaying the relapse-free 
survival (RFS) using the Kaplan-Meier plotter (http://
kmplot.com/analysis/) [39]. Kaplan–Meier survival 
curve, log-rank P value and HR with 95 % confidence 
intervals were calculated and plotted in R using Bio-
conductor packages.
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